Special Issue

Recent Advances in Cancer Diagnosis and Therapy

Message from the Guest Editors

According to the World Health Organization report, cancer continues to be one of the leading causes of death worldwide. A cancer diagnosis is often made in advanced stages when it is associated with a high risk of recurrence and metastasis. Thus, the early diagnosis of cancer is one the most significant strategies to decrease the cancer mortality rate. Currently, the approach for cancer diagnosis includes non-invasive imaging exams combined with molecular biology techniques and the pathological examination of tissue samples to establish the type and stage of the cancer. In addition, another main cancer-related research priority is to develop new therapeutic tools with a high response rate and limited side-effects. This Special Issue aims to provide a platform for gathering updated research in cancer-related diagnosis and treatment, which may improve the prognosis of the oncologic patient.

Guest Editors

Dr. Adriana Grigoraș

Department of Morphofunctional Sciences I, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania

Dr. Hsin-Sheng Yang

Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, KY, USA

Deadline for manuscript submissions

closed (30 July 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/211564

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

